We’ve updated our Privacy Policy in accordance with changes to data protection laws. If you’d like to read our Privacy Policy, please click here.
PEBEQ is the first validated premature ejaculation test to be developed in the United States and follow the FDA guidelines.
Plethora Solutions is a specialty pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders since 2007. Plethora has developed a simple test for doctors and patients to diagnose and manage a common condition, premature ejaculation (PE). This tool, the Premature Ejaculation Bothersome Evaluation Questionnaire (PEBEQ), has been developed in accordance with FDA guidelines and Plethora has discussed this test with the FDA itself. The test is available on the website here.
The diagnosis and treatment of urological conditions represents an expanding market with many poorly met medical needs that offer significant commercial potential for new pharmaceutical products and medical devices.
The Company's principal product is a treatment remedy for male premature ejaculation which obtained marketing authorization from the European Commission on 19 November 2013. Although the European MAA has been authorized by the European Commission, information contained on this website is provided for business development and investor relations purposes only. Patients who suffer or believe they suffer from PE should contact their physician in the first instance.
“Premature ejaculation is a male sexual dysfunction characterised by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.”
The International Society for Sexual Medicine (ISSM)
